A randomized, controlled trial of maintenance interferon therapy for patients with chronic hepatitis C virus and persistent viremia

Gastroenterology

Volumn 117, Issue 5, 1999, Pages 1164-1172

  Shiffman, M L ^a   Hofmann, C M ^a   Contos, M J ^a   Luketic, V A ^a   Sanyal, A J ^a   Sterling, R K ^a   Ferreira Gonzalez, A ^a   Mills, A S ^a   Garret, C ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; VIRUS RNA;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHRONIC HEPATITIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOTHERAPY; LIVER BIOPSY; MAJOR CLINICAL STUDY; MALE; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT PLANNING; VIRUS DETECTION; VIRUS LOAD;

EID: 0032736213     PISSN: 00165085     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0016-5085(99)70402-6     Document Type: Article

References (46)

1. JG McHutchinson S Gordon ER Schiff ML Shiffman WM Lee VK Rustgi Z Goodman MH Ling S Cort JK. Albrecht Interferon alfa-2b monotherapy versus interferon alfa 2b plus ribavirin as initial treatment for chronic hepatitis C: results of a US multi-center randomized controlled trial N Engl J Med 339 1998 1485 1492
2. GL Davis R Esteban-Mur VK Rustgi J Hoefs S Gordon C Trepo ML Shiffman S Zeuzem A Craxi MH Ling J. Albrecht Recombinant interferon alfa-2b alone or in combination with ribavirin for retreatment of interferon relapse in chronic hepatitis C N Engl J Med 339 1998 1493 1499
3. T Poynard P Marcellin SS Lee C Niederau GS Minuk G Ideo V Bain J Heathcote S Zeuzem C Trepo J. Albrecht Randomized trial of interferon alfa-2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alfa-2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C Lancet 352 1998 1426 1432
4. O Reichard G Norkrans A Fryden JH Braconier A Sonnerborg O. Weiland Randomized, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish study group Lancet 351 1998 83 87
5. ML Shiffman CH Hofmann VA Luketic AJ Sanyal MA Contos AS. Mills Gradual reduction in interferon dose reduces the incidence of relapse in patients with chronic hepatitis C: results of a randomized controlled trial Hepatology 24 1996 21 26
6. O Reichard H Glaumann A Fryden G Norkrans R Schvarcz A Sonnerborg ZB Yun O. Weiland Two-year biochemical, virologic and histologic follow-up in patients with chronic hepatitis C responding in a sustained fashion to interferon alfa-2b treatment Hepatology 21 1995 918 922
7. P Marcellin N Boyer A Gervais M Martinot M Pouteau C Castelnau A Kilani J Areias A Auperin JP Benhamou C Degott S Erlinger Long term histologic improvement and loss of detectible intrahepatic HCV-RNA in patients with chronic hepatitis C and sustained response to interferon-α therapy Ann Intern Med 127 1997 875 881
8. GL Davis LA Balart ER Schiff K Lindsay HC Bodenheimer Jr RP Perrillo W Carey IM Jacobson J Payne J. Dienstag Treatment of chronic hepatitis C with recombinant interferon alpha: a multicenter, randomized, controlled trial N Engl J Med 321 1989 1501 1506
9. AM DiBisceglie P Martin C Kassianides M Lisker-Melman L Murray J Waggoner Z Goodman SM Banks JH. Hoofnagle Recombinant interferon alfa therapy for chronic hepatitis C N Engl J Med 321 1989 1506 1510
10. P Marcellin N Boyer E Giostra C Degott AM Courouce F Degos H Coppere P Cales P Couzigou JP. Benhamou Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France Hepatology 13 1991 393 397
11. X Causse H Godinot M Chevallier P Chossegros F Zoulim D Ouzan JP Heyraud T Fontanges J Albrecht C Meschievitz C. Trepo Comparison of 1 or 3 mU of interferon alpha-2b and placebo in patients with chronic non-A, non-B hepatitis Gastroenterology 101 1991 497 502
12. L Chemello P Bonetti L Cavalletto F Talato V Donadon P Casarin F Belussi M Frezza F Noventa P. Pontisso Randomized trial comparing three different regimens of alpha-2a-interferon in chronic hepatitis C Hepatology 22 1995 700 706
13. T Poynard P Bedossa M Chevallier P Mathurin C Lemonnier C Trepo P Couzigou JL Payen M Sajus JM Costa M Vidaud JC Chaput the multicenter study group A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis N Engl J Med 332 1995 1457 1462
14. ML Shiffman CM Hofmann EB Thompson A Ferreira-Gonzalez MJ Contos A Koshy VA Luketic AJ Sanyal AS Mills C. Garrett Relationship between biochemical, virologic and histologic response during interferon treatment of chronic hepatitis C Hepatology 26 1997 780 785
15. ML. Shiffman Improvement in liver histopathology associated with interferon therapy in patients with chronic hepatitis C Viral Hepat Rev 5 1999 27 43
16. M Yano H Kumada M Kage K Ikeda K Shimamatsu O Inoue E Hashimoto JH Lefkowitch J Ludwig K. Okuda The long term pathological evolution of chronic hepatitis C Hepatology 23 1996 1334 1340
17. T Poynard P Bedossa P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C Lancet 349 1997 825 832
18. M Guido M Rugge L Chemello G Leandro G Fattovich G Giustina M Cassaro A. Alberti Liver stellate cells in chronic viral hepatitis: the effect of interferon therapy J Hepatol 24 1996 301 307
19. A Mallat A Preaux S Blazejewski J Rosenbaum D Dhumeaux P. Mavier Interferon alfa and gamma inhibit proliferation and collagen synthesis of human Ito cells in culture Hepatology 21 1995 1003 1010
20. DC Rockey J. Chung Interferon gamma inhibits lipocyte activation and extracellular matrix mRNA expression during experimental liver injury: implications for treatment of hepatic fibrosis J Invest Med 42 1994 660 670
21. RG Knodell KG Ishak WC Black TS Chen R Craig N Kaplowitz TW Kiernan J. Wollman Formulation and application of a numerical scoring system for assessing histological activity in asymptomatic chronic active hepatitis Hepatology 1 1981 431 435
22. A Ferreira-Gonzalez ML Shiffman DH Lofland MR Langley DW Gainey CT Garrett Assessing clinical utility of hepatitis C virus quantitative RT-PCR data. Implications for identification of responders among α-interferon treated patients Mol Diag 1 1996 109 120
23. ML Shiffman KR Reddy CM Hofmann K Roache A Ferreira-Gonzalez M De Medina CT Garrett L Jeffers ER. Schiff Comparison of Chironb-DNA assay to Roche Amplicor quantitative PCR and Knodell score in the assessment of patients with chronic hepatitis C virus infection Hepatology 24 1996 385A
24. M Martinot-Peignoux P Marcellin M Pouteau C Castelnau N Boyer M Poliquin C Degott I Descombes V Le Breton V Milotova JP Benhamou S. Erlinger Pretreatment serum hepatitis C virus RNA levels and hepatitis C virus genotype are the main and independent prognostic factors of sustained response to interferon alfa therapy in chronic hepatitis C Hepatology 22 1995 1050 1056
25. NN Zein J Rakela EL Krawitt KR Reddy T Tominaga DH. Persing Hepatitis C virus genotypes in the United States: epidemiology, pathogenicity, and response to interferon therapy Ann Intern Med 125 1996 634 639
26. MJ Tong KR Reddy WM Lee PJ Pockros JC Hoefs EB Keeffe FB Hollinger Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial Hepatology 26 1997 747 754
27. GC Ferrell BR Bacon RD. Goldin Lymphoblastoid interferon alfa-n1 improves the long term response to a 6 month course of treatment in chronic hepatitis C compared with recombinant interferon alfa-2b: results of an international randomized controlled trial Hepatology 27 1998 1121 1127
28. AM Gressner MG. Bachem Cellular sources of noncolangenous matrix proteins: role of fat storing cells in fibrogenesis Semin Liver Dis 10 1990 30 46
29. SL. Friedman The cellular basis of hepatic fibrosis: mechanisms and treatment strategies N Engl J Med 328 1993 1828 1835
30. V Duchatelle P Marcellin E Giostra L Bregeaud M Pouteau N Boyer A Auperin Changes in liver fibrosis at the end of alpha interferon therapy and 6 to 18 months later in patients with chronic hepatitis C: quantitative assessment by a morphometric method J Hepatol 29 1998 20 28
31. J Risteli L. Risteli Analyzing connective tissue metabolites in human serum. Biochemical, physiologic and methodological aspects J Hepatol 22 suppl 2 1995 77 81
32. G Biagini G. Ballardini Liver fibrosis and extracellular matrix J Hepatol 8 1989 115 124
33. O Niemela L Risteli EA Sotaniemi J. Risteli Type IV collagen and laminin-related antigens in human serum in alcoholic liver disease Eur J Clin Invest 15 1985 132 137
34. A Engstrom-Laurent L Loof A Nyberg T. Schroder Increased serum levels of hyaluronate in liver disease Hepatology 5 1985 638 642
35. F Capra M Casaril GB Gabrielli P Tognella A Rizzi L Dolci R Colombari P Mezzelani R Corrocher G. De Sandre Alfa-interferon in the treatment of chronic viral hepatitis: effects on fibrogenesis serum markers J Hepatol 18 1993 112 118
36. JC Teran KD Mullen JH Hoofnagle AJ McCullough Decrease in serum levels of markers of hepatic connective tissue turnover during and after treatment of chronic hepatitis B with interferon-α Hepatology 19 1994 849 856
37. AH Baggenstoss RD Soloway WHJ Summerskill LR Elveback LJ. Schoenfield Chronic active liver disease: the range of histologic lesions, their response to treatment and evolution Hum Pathol 3 1972 183 198
38. WG Cooksley RA Bradbear W Robinson M Harrison JW Halliday LW Powell HS Ng CS Seah K Okuda PJ. Scheuer The prognosis of chronic active hepatitis without cirrhosis in relation to bridging necrosis Hepatology 6 1986 345 348
39. J DeGote J Fevery L. Lepoutre Long term follow-up of chronic hepatitis of moderate severity Gut 19 1978 510 513
40. O Dietrichson P. Christoffersen The prognosis of chronic aggressive hepatitis Scand J Gastroenterol 12 1977 289 295
41. M Yano H Kumada M Kage K Ikeda K Shimamatsu O Inoue E Hashimoto JH Lefkowitch J Ludwig K. Okuda The long term pathological evolution of chronic hepatitis C Hepatology 23 1996 1334 1340
42. T Poynard P Bedossa P. Opolon Natural history of liver fibrosis progression in patients with chronic hepatitis C Lancet 349 1997 825 832
43. S Nishiguchi T Kuroki S Nakatani H Morimoto T Takeda S Nakajima S Shiomi Randomized trial of effects of interferon-α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis Lancet 346 1995 1051 1055
44. G Fattovich G Giustina F Degos G Diodati F Tremolada F Nevens P Almasio A Solinas JT Brouwer H Thomas G Realdi R Corrocher SW. Schalm Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in European patients with cirrhosis type C J Hepatol 27 1977 201 205
45. G Mazzella E Accogli S Sottili D Festi M Orsini A Salzetta V Novelli A Cipolla C Fabbri A Pezzoli E. Roda Alpha-interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis J Hepatol 24 1996 141 147
46. Y Imai S Kawata S Tamura I Yabuuchi S Noda M Inada Y Maeda Y Shirai T Fukuzaki I Kaji H Ishikawa Y Matsuda M Nishikawa K. Seki Relation of interferon therapy and hepatocellular carcinoma in patients with chronic hepatitis C Ann Intern Med 129 1998 94 99